Deventer, 11 March 2025 – Portfolio company Sencure, a leader in wearable health technology, has secured a €3.9 million additional investment in its Series B2 funding round, bringing the total B round up to € 7.9 million. Its total funding—including non-dilutive sources—amounts to over €15 million in the last 4 years.
At the heart of Sencure’s success is its flagship product, the SNCE800 IC —a high-performance, low-power chip that’s setting new standards for wearable medical devices. The SNCE800 is poised to power a new generation of wearable health products, from EEG-enabled earbuds and headbands to ECG patches and EMG-based wearables.
As the global demand for compact, efficient medical devices surges—driven by an aging population and rapid healthcare digitalization—Sencure’s innovations are leading the charge in creating smarter, more efficient solutions.
With investment backing from Cottonwood Technology Fund, Bluegrass Ventures, NV NOM, and 819 Capital Partners, Sencure is gearing up for a major expansion. Central to this growth is the opening of a state-of-the-art facility at the Noviotech Campus in Nijmegen. “We are thrilled to welcome Bluegrass Ventures to our family of investors and to strengthen our existing partnerships,” said Sencure CEO Dick van Waes. “This funding propels us into the next phase of growth and innovation.”
Sencure has also welcomed Getlin Visser to its Supervisory Board. With a deep-rooted passion for technology and healthcare innovation, Visser brings invaluable expertise to guide Sencure’s next steps. “I am excited to join Sencure’s Supervisory Board and support their mission to revolutionize wearable technology,” said Visser. “Their approach to healthcare solutions is visionary, and I look forward to being part of their journey.”
Additionally, the company’s newly appointed VP of R&D, William Trilsbeek, will spearhead efforts in Nijmegen. “Leading this team in Nijmegen is an incredible opportunity,” said Trilsbeek. “Sencure’s relentless pursuit of innovation is inspiring, and I’m eager to contribute to groundbreaking solutions that will shape the future of healthcare.”
With fresh capital, an expanded team, and cutting-edge technology, Sencure is well on its way to transforming the wearable health market. As the company continues its mission to miniaturize and enhance medical wearables, the future looks brighter than ever.
We invested in Sencure through 819 Evergreen Fund.
